Initial

FINNEST INVESTMENTS (UK) A SUBSIDUARY OF BNP GROUP (DUBAI) AND ZERO CARBON TECHNOLOGIES (UK) JOINTLY ANNOUNCE INVESTMENT AGREEMENT

Retrieved on: 
Tuesday, December 12, 2023
Carbon, Banja Luka Stock Exchange, Investment, Recycling, Funding, Nature, CBOE, USD, Waste, Note, Legislation, Finance, Documentation, Initial, Equity, Transaction, Party, Stock exchange, Share (finance), Security (finance), Commercial property, Real estate, Bond

November 27 th, 2023, London, Dubai, FinNest Investments and Zero Carbon Technologies (“ZCT or the Company”) jointly announce an equity and debt investment, into ZCT for USD 100 million, by way of a corporate bond to be listed on the Afrinex Exchange.

Key Points: 
  • November 27 th, 2023, London, Dubai, FinNest Investments and Zero Carbon Technologies (“ZCT or the Company”) jointly announce an equity and debt investment, into ZCT for USD 100 million, by way of a corporate bond to be listed on the Afrinex Exchange.
  • The remaining three (3) directors are Sir Tony Baldry Chairman, Chris Farnworth, CEO, and John Armstrong.
  • Sir Tony Baldry, Chairman said: we are very pleased to welcome .finest and BNP Group companies to Zero Carbon Technologies.
  • TheFinNestt/BNP Group under the leadership of Biswanath Patnaik brings together a dynamic team, to accelerate thegrowth of ZCT.

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, November 3, 2023
Gene editing, International Symposium on Endovascular Therapy, FDA, Research, Food, Rhodopsin, Human, Congress, Fragile X syndrome, G&A, Liver, CFTR, Chromosomal translocation, Regulation of tobacco by the U.S. Food and Drug Administration, Cell, Initial, R, Society, ASH, RHO, Tissue, Lung, Cystic fibrosis, Prime editing, Gene, Composition, Abstract, LNP, Eye, Safety, European Society of Clinical Microbiology and Infectious Diseases, Investment, CGD, Patient, Retina, NHP, Patent, D, Vaccine, Pharmaceutical industry, Fine chemical, Beef cattle, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

Key Points: 
  • 11,795,452 --
    CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
  • Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
  • In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
  • Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.

LSL Pharma Group Announces Closing of First Tranche of Convertible Debentures Offering

Retrieved on: 
Wednesday, November 1, 2023
Capital market, TSX Venture Exchange, Sale, CAD, Finance Secretary (India), Base rate, LSL, Public expenditure, Policy, EBITDA, Affordable Care Act Health Insurance Rate Review Program, Plan, IA, Acquisition, Exercise, Initial, Offering, Bank statement, Prospectus, Business, Class B share, Conversion, Security (finance), Life insurance, Debenture

The net proceeds of the Offering will be used for working capital, capital expenditures, and for general corporate purposes.

Key Points: 
  • The net proceeds of the Offering will be used for working capital, capital expenditures, and for general corporate purposes.
  • The Offering was led by iA Capital Markets as sole agent and sole bookrunner (the “Agent”).
  • In connection with the first tranche of the Offering, the Company paid to the Agent a cash commission of $160,510 and issued 229,300 broker warrants (the “Broker Warrants”).
  • All securities issued pursuant to the Offering are subject to the applicable statutory hold period of four months and one day from November 1, 2023 (the “Initial Closing Date”).

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Retrieved on: 
Wednesday, November 1, 2023
Euronext, Gene editing, AstraZeneca, IND, Therapy, Rare, Alexion, Doctor of Philosophy, Research, Initial, MOU, UCART123, File, Collaboration, Investment, IP, Patient, Pharmaceutical industry, Security (finance), Cellectis

Under the terms of the Collaboration Agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products.

Key Points: 
  • Under the terms of the Collaboration Agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products.
  • As part of the Collaboration Agreement, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 candidate products could be explored for development.
  • Pursuant to the Collaboration Agreement, Cellectis’ research costs under the collaboration will be funded by AstraZeneca and Cellectis will receive an upfront payment of $25M.
  • As a condition to the signing of the Collaboration Agreement, AstraZeneca has agreed to make an initial equity investment of $80M in Cellectis by subscribing for 16,000,000 ordinary shares, at a price of $5.00 per share (the “Initial Investment”).

Astra Announces Closing of Additional Debt Financing and Waiver of Previously Announced Defaults

Retrieved on: 
Monday, November 6, 2023
Technology, Aerospace, Manufacturing, Satellite, Documentation, Sale, Security (finance), ASTR, Warrant, Note, Initial, Term sheet, Common stock, Common, LLP, Sheet, Astra (American spaceflight company)

This Initial Financing is connected to Astra’s announcement in a report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 23, 2023 of the execution of a non-binding term sheet (the “Term Sheet”).

Key Points: 
  • This Initial Financing is connected to Astra’s announcement in a report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 23, 2023 of the execution of a non-binding term sheet (the “Term Sheet”).
  • The Term Sheet contemplates a financing of at least $15.0 million, from the Investors and other potential investors, and up to $25.0 million (the “Proposed Financing”).
  • Astra is in continuing discussions concerning the Proposed Financing with the Investors.
  • The Bridge Notes, the Warrants and any securities issued in connection with the Proposed Financing may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

Pioneers and Innovators in Psilocybin Treatments and How Big Pharma Wants in on the Game

Retrieved on: 
Thursday, October 19, 2023
Post-traumatic stress disorder, Big Pharma, FDA, CAD, KAYS, Patent, Food, Oregon Health Authority, Therapy, Sacredness, COMPASS, DSM-IV codes, News, Pharma, FDT, US Foods, Research, Initial, OTCQB, Psilocybin, Yoga, Breakthrough therapy, Private placement, Good, Ōtsuka, Eating, Anorexia nervosa, Depression, OHA, Medication, Anxiety, Investment, Patient, Neuropsychiatry, TRD, Pulse, Mental health, Pharmaceutical industry, Nursing

As psilocybin and other alternative health innovators try to shape the future of mental health, Pharma and traditional healthcare investors are watching and waiting to get their share.

Key Points: 
  • As psilocybin and other alternative health innovators try to shape the future of mental health, Pharma and traditional healthcare investors are watching and waiting to get their share.
  • (OTCQB: KAYS) is the only U.S. public company engaged in securing an Oregon Health Authority ("OHA") license to open a psilocybin treatment center.
  • Kaya Holdings just announced that it has closed an additional round of bridge financing targeted to complete KAYS' planned psilocybin treatment center in Portland, Oregon.
  • Reporting on the Mindset Pharma deal, Psychedelicspotlight.com said , "Big Pharma has certainly taken note of the potential therapeutic benefits of psychedelics.

BlueFire Equipment Corp (BLFR) Acquires Screaming Eagle Partners, LLC, a Cashflow Positive Family-Owned Oil & Gas Company in Texas

Retrieved on: 
Thursday, October 19, 2023
Tax, Austin Chalk, EBITDA, CCO, Acquisition, Initial, CIR, Exponentiation, Common stock, Eagle, PCAOB, Marketing, Interim, CFO, Management, Self storage, Oil, Bedias Creek

During the period ended July 30, 2023, Screaming Eagle generated revenues of $2,065,219, net operating income (EBITDA) of $441,021, and total assets of $7,257,352.

Key Points: 
  • During the period ended July 30, 2023, Screaming Eagle generated revenues of $2,065,219, net operating income (EBITDA) of $441,021, and total assets of $7,257,352.
  • Through an all-stock transaction, the owners merged Screaming Eagle into BLFR in return for the issuance of 45,000,000 shares of Preferred Stock Series A and 810,000 shares of Preferred Stock Series B shares.
  • Furthermore, the appointment of Kirk Yariger as Chairman of the Board and Jonas Crafts as Directors of the Board of BLFR.
  • Engage a branding and marketing firm for the Company’s new direction upon the completion of the stock symbol and name change.

Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress

Retrieved on: 
Wednesday, October 18, 2023
Neoplasm, GBM, AstraZeneca, ATM, MD, Ben, CNS, Initial, Barrow Neurological Institute, Cerebrospinal fluid, Radiation, Clinical trial, Oncology, Blood, European Society of Gynaecological Oncology, Patient, Glioblastoma, Pharmaceutical industry, Medical imaging

This novel Phase 0/1 study demonstrated, for the first time in human, that AZD1390 may be a potent radio-sensitizer in patients with glioblastoma (GBM).

Key Points: 
  • This novel Phase 0/1 study demonstrated, for the first time in human, that AZD1390 may be a potent radio-sensitizer in patients with glioblastoma (GBM).
  • “Exploring ATM as a target for brain tumor precision medicine is an important priority for our field and our patients,” says Dr. Sanai.
  • All patients exceeded a predefined threshold for brain tumor drug penetration, qualifying them for continued therapeutic dosing with AZD1390 plus radiotherapy.
  • This study is still accruing and a Phase 0/1 clinical trial of AZD1390 in newly diagnosed MGMT-unmethylated glioblastoma is now underway.

Piedmont Lithium Partners With Vinland Lithium to Advance the Killick Lithium Project in Newfoundland

Retrieved on: 
Wednesday, October 11, 2023
Semiconductor, Mining, Minerals, Technology, Batteries, Mobile, Wireless, Natural Resources, Lithium, Partnership, Multimedia, Initial, Piedmont Lithium, Acquisition, ASX, Australian Securities Exchange, PLL, Project, Weather, Risk, Transport, Legislation, NSR, AIM, Marketing, Comment, Sale, Accident, Frequency addition source of optical radiation, ALL, Carolina, Soil, Security (finance), Uranium mining

Piedmont has agreed to pay C$2 million for a 19.9% equity interest in Vinland Lithium Inc. (“Vinland Lithium”), a new entity established with Sokoman Minerals Corp. (“Sokoman Minerals”) (40.1%) and Benton Resources Inc. (“Benton Resources”) (40.1%).

Key Points: 
  • Piedmont has agreed to pay C$2 million for a 19.9% equity interest in Vinland Lithium Inc. (“Vinland Lithium”), a new entity established with Sokoman Minerals Corp. (“Sokoman Minerals”) (40.1%) and Benton Resources Inc. (“Benton Resources”) (40.1%).
  • The Company also may earn up to a 62.5% equity interest in Killick Lithium Inc., a wholly-owned subsidiary of Vinland Lithium holding a 100% interest in the Killick Lithium Project (“Killick Lithium” or the “Project”), through a staged investment agreement.
  • View the full release here: https://www.businesswire.com/news/home/20231011399097/en/
    Geologically, the Killick Lithium property is analogous to the Carolina Tin-Spodumene Belt, which hosts Piedmont’s Carolina Lithium project.
  • Killick Lithium grants Piedmont exclusive marketing rights for the promotion and sale of any lithium products produced from the Project on a life of mine basis.

Maidaan Games to Imminently Launch $MDN Token - Your Key to Web3 Marketplaces

Retrieved on: 
Thursday, September 28, 2023
Crypto, Blockchain, NFT, IGO, INO, Multimedia, MDN, Initial, Non-fungible token, Ball, Cryptocurrency, Video game, Online shopping, Maidaan

DUBAI, UAE, Sept. 28, 2023 /PRNewswire/ -- Maidaan, the trailblazing force in the gaming industry, is proud to announce the launch of the MDN token, an innovator in gaming and blockchain. This transformative token promises an enriched gaming experience and opens doors to unprecedented opportunities in the metaverse gaming community.

Key Points: 
  • DUBAI, UAE, Sept. 28, 2023 /PRNewswire/ -- Maidaan, the trailblazing force in the gaming industry, is proud to announce the launch of the MDN token, an innovator in gaming and blockchain.
  • This transformative token promises an enriched gaming experience and opens doors to unprecedented opportunities in the metaverse gaming community.
  • The MDN token plays a crucial role in the Maidaan ecosystem, offering opportunities for everyone involved.
  • Plus, rewards such as in-game assets and NFTs, enhance your gaming experience and investment opportunities within the Maidaan ecosystem.